Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening
Author:
Open Access
- 1 January 2013
- journal article
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. 5, 1-3
Abstract
Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening Keith V Nance Medical Directory of Cytology, Rex Hospital, Raleigh, and Department of Pathology, The University of North Carolina School of Medicine, Chapel Hill, NC, USAKeywords
This publication has 13 references indexed in Scilit:
- Prospective Study of HPV16 Viral Load and Risk of In Situ and Invasive Squamous Cervical CancerCancer Epidemiology, Biomarkers & Prevention, 2013
- Follow-up Outcomes of a Large Cohort of Low-Risk Women With Negative Imaged Liquid-Based Cytology and Negative HPV Test ResultsAmerican Journal of Clinical Pathology, 2013
- Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus–Negative ASC-H Cervical Screening Test ResultsAmerican Journal of Clinical Pathology, 2012
- Practice Patterns in Cervical Cancer Screening and Human Papillomavirus TestingAmerican Journal of Clinical Pathology, 2012
- Screening Test Results Associated With Cancer Diagnoses in 287 Women With Cervical Squamous Cell CarcinomaArchives of Pathology & Laboratory Medicine, 2012
- A Long-term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia Among 20,000 Women in the Portland Kaiser Cohort StudyCancer Epidemiology, Biomarkers & Prevention, 2011
- The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.2009
- Comparison of the Hybrid Capture II Assay With the Human Papillomavirus DNA Chip Test for the Detection of High-Grade Cervical LesionsInternational Journal of Gynecological Cancer, 2009
- The Expanded Use of HPV Testing in Gynecologic Practice per ASCCP-Guided Management Requires the Use of Well-Validated AssaysAmerican Journal of Clinical Pathology, 2007
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999